S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44

Lyra Therapeutics (LYRA) Stock Forecast, Price & News

+0.19 (+3.89%)
(As of 05/16/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
14,594 shs
Average Volume
168,110 shs
Market Capitalization
$65.96 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LYRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Lyra Therapeutics logo

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$280 thousand
Book Value
$2.64 per share


Net Income
$-43.51 million
Pretax Margin




Free Float
Market Cap
$65.96 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.61 out of 5 stars

Medical Sector

973rd out of 1,423 stocks

Surgical & Medical Instruments Industry

103rd out of 138 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Lyra Therapeutics (NASDAQ:LYRA) Frequently Asked Questions

Is Lyra Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lyra Therapeutics stock.
View analyst ratings for Lyra Therapeutics
or view top-rated stocks.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 375,600 shares, an increase of 50.0% from the April 15th total of 250,400 shares. Based on an average daily trading volume, of 222,400 shares, the short-interest ratio is presently 1.7 days.
View Lyra Therapeutics' Short Interest

When is Lyra Therapeutics' next earnings date?

Lyra Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Lyra Therapeutics

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its quarterly earnings results on Wednesday, March, 9th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.23. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $1 million.
View Lyra Therapeutics' earnings history

Who are Lyra Therapeutics' key executives?
Lyra Therapeutics' management team includes the following people:
  • Dr. Maria Palasis Ph.D., CEO, Pres & Director (Age 56, Pay $848.19k)
  • Mr. Jason Cavalier, CFO, Treasurer & Sec.
  • Mr. R. Donald Elsey MBA, Advisor (Age 68, Pay $640.11k)
  • Ms. Corinne Noyes, Sr. VP of Commercial Strategy & Market Devel. (Age 54, Pay $426.73k)
  • Dr. Harlan W. Waksal M.D., Exec. Chairman (Age 69)
  • Dr. Carmichael S. Roberts Jr., Ph.D., Co-Founder (Age 54)
  • Mr. Ray Knox, VP of Operations
  • Dr. Robert Richard Ph.D., Sr. VP of Technical Operations (Age 65)
  • Ms. Vineeta Belanger Ph.D., Sr. VP of Clinical Affairs
  • Ms. Pamela E. Nelson, Sr. VP of Regulatory Affairs (Age 52)
What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Clearline Capital LP (0.92%), Renaissance Technologies LLC (0.13%) and JPMorgan Chase & Co. (0.06%). Company insiders that own Lyra Therapeutics stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta and Nbvm Gp, Llc.
View institutional ownership trends for Lyra Therapeutics

Which institutional investors are selling Lyra Therapeutics stock?

LYRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Lyra Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Lyra Therapeutics stock?

LYRA stock was purchased by a variety of institutional investors in the last quarter, including Clearline Capital LP, and JPMorgan Chase & Co.. Company insiders that have bought Lyra Therapeutics stock in the last two years include C Ann Merrifield, Edward T Anderson, Harlan Waksal, and Nbvm Gp, Llc.
View insider buying and selling activity for Lyra Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $5.07.

How much money does Lyra Therapeutics make?

Lyra Therapeutics has a market capitalization of $65.96 million and generates $280 thousand in revenue each year. The company earns $-43.51 million in net income (profit) each year or ($3.29) on an earnings per share basis.

How many employees does Lyra Therapeutics have?

Lyra Therapeutics employs 53 workers across the globe.

What is Lyra Therapeutics' official website?

The official website for Lyra Therapeutics is www.lyratherapeutics.com.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-373-4600 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.